Pathogenesis, clinical picture, and current therapy of rosacea;Pathogenese, Klinik und aktuelle Therapie der Rosazea

Hautarzt

Volumn 67, Issue 1, 2016, Pages 69-84

  Gonser, L I ^a   Gonser, C E ^b   Schaller, M ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Demodex; Erythematotelangiectatic rosacea; Ocular rosacea; Papulopustular rosacea; Phymatous rosacea

Indexed keywords

AZELAIC ACID; BRIMONIDINE; DOXYCYCLINE; IVERMECTIN; METRONIDAZOLE; ANTIINFLAMMATORY AGENT; DERMATOLOGICAL AGENT;

ARTICLE; CLINICAL FEATURE; ERYTHEMATOTELANGIECTATIC ROSACEA; HUMAN; PAPULOPUSTULAR ROSACEA; PATHOGENESIS; PHYMATOUS ROSACEA; ROSACEA; EPILUMINESCENCE MICROSCOPY; EVIDENCE BASED MEDICINE; PROCEDURES; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; DERMATOLOGIC AGENTS; DERMOSCOPY; EVIDENCE-BASED MEDICINE; HUMANS; ROSACEA; TREATMENT OUTCOME;

EID: 84954368360     PISSN: 00178470     EISSN: 14321173     Source Type: Journal    
DOI: 10.1007/s00105-015-3735-5     Document Type: Article

References (34)

1. Gauwerky K, Klovekorn W, Korting HC et al (2009) Rosacea. J Dtsch Dermatol Ges 7:996–1003
2. Steinhoff M, Buddenkotte J, Aubert J et al (2011) Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 15:2–11
3. Yamasaki K, Gallo RL (2009) The molecular pathology of rosacea. J Dermatol Sci 55:77–81
4. Schauber J, Gallo RL (2009) Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol 124:R13–R18
5. Yamasaki K, Schauber J, Coda A et al (2006) Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 20:2068–2080
6. Yamasaki K, Di Nardo A, Bardan A et al (2007) Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 13:975–980
7. Yamasaki K, Kanada K, Macleod DT et al (2011) TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol 131:688–697
8. Sattler EC, Maier T, Hoffmann VS et al (2012) Noninvasive in vivo detection and quantification of Demodex mites by confocal laser scanning microscopy. Br J Dermatol 167:1042–1047
9. Chen W, Plewig G (2014) Human demodicosis: revisit and a proposed classification. Br J Dermatol 170:1219–1225
10. Kulka M, Sheen CH, Tancowny BP et al (2008) Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 123:398–410
11. Schwab VD, Sulk M, Seeliger S et al (2011) Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 15:53–62
12. Lehmann P (2005) [Rosacea. Clinical features, pathogenesis and therapy]. Hautarzt 56:871–885. (quiz 886–887)
13. Wilkin J, Dahl M, Detmar M et al (2002) Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 46:584–587
14. Melnik BJT (2012) Akne und Rosazea. In: Plewig G Landthaler M, Burgdorf W, Hertl M, Ruzicka T (Hrsg) Braun-Falco’s Dermatologie, Venerologie und Allergologie. Springer, Berlin, S 1218–1225
15. Spoendlin J, Voegel JJ, Jick SS et al (2012) A study on the epidemiology of rosacea in the U.K. Br J Dermatol 167:598–605
16. Reinholz M, Tietze JK, Kilian K et al (2013) Rosacea – S1 guideline. J Dtsch Dermatol Ges 11(768–780):768–779
17. Drolet B, Paller AS (1992) Childhood rosacea. Pediatr Dermatol 9:22–26
18. Chamaillard M, Mortemousque B, Boralevi F et al (2008) Cutaneous and ocular signs of childhood rosacea. Arch Dermatol 144:167–171
19. Seite S, Benech F, Berdah S et al (2013) Management of rosacea-prone skin: evaluation of a skincare product containing Ambophenol, Neurosensine, and La Roche-Posay Thermal spring water as monotherapy or adjunctive therapy. J Drugs Dermatol 12:920–924
20. Liste R (2015)
21. Van Zuuren EJ, Kramer SF, Carter BR et al (2011) Effective and evidence-based management strategies for rosacea: summary of a Cochrane systematic review. Br J Dermatol 165:760–781
22. Fowler J, Jarratt M, Moore A et al (2012) Once-daily topical brimonidine tartrate gel 0.5 % is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol 166:633–641
23. Moore A, Kempers S, Murakawa G et al (2014) Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5 % for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol 13:56–61
24. Allen KJ, Davis CL, Billings SD et al (2007) Recalcitrant papulopustular rosacea in an immunocompetent patient responding to combination therapy with oral ivermectin and topical permethrin. Cutis 80:149–151
25. Forton F, Seys B, Marchal JL et al (1998) Demodex folliculorum and topical treatment: acaricidal action evaluated by standardized skin surface biopsy. Br J Dermatol 138:461–466
26. Kocak M, Yagli S, Vahapoglu G et al (2002) Permethrin 5 % cream versus metronidazole 0.75 % gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study. Dermatology 205:265–270
27. Goldman D (2001) Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol 44:995–998
28. Del Rosso JQ, Webster GF, Jackson M et al (2007) Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol 56:791–802
29. Pfeffer I, Borelli C, Zierhut M et al (2011) Treatment of ocular rosacea with 40 mg doxycycline in a slow release form. J Dtsch Dermatol Ges 9:904–907
30. Torresani C, Pavesi A, Manara GC (1997) Clarithromycin versus doxycycline in the treatment of rosacea. Int J Dermatol 36:942–946
31. Schaller M, Sander CA, Plewig G (2003) Demodex abscesses: clinical and therapeutic challenges. J Am Acad Dermatol 49:S272–S274
32. Park H, Del Rosso JQ (2011) Use of oral isotretinoin in the management of rosacea. J Clin Aesthet Dermatol 4:54–61
33. Gollnick H, Blume-Peytavi U, Szabo EL et al (2010) Systemic isotretinoin in the treatment of rosacea – doxycycline- and placebo-controlled, randomized clinical study. J Dtsch Dermatol Ges 8:505–515
34. Hsu CC, Lee JY (2012) Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective beta-adrenergic blocker. J Am Acad Dermatol 67:491–493